Get the Stockscreener App
1.53
1.92%
-0.03
After Hours:
1.60
0.07
+4.58%
Cellectar Biosciences Inc stock is traded at $1.53, with a volume of 199.93K.
It is down -1.92% in the last 24 hours and down -24.63% over the past month.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
See More
Previous Close:
$1.56
Open:
$1.57
24h Volume:
199.93K
Relative Volume:
0.63
Market Cap:
$65.21M
Revenue:
-
Net Income/Loss:
$-37.75M
P/E Ratio:
-0.4608
EPS:
-3.32
Net Cash Flow:
$-30.91M
1W Performance:
-1.92%
1M Performance:
-24.63%
6M Performance:
-50.80%
1Y Performance:
-28.50%
1-Day Range:
$1.525
$1.61
1-Week Range:
$1.385
$1.63
52-Week Range:
$1.385
$4.45
Cellectar Biosciences Inc Stock (CLRB) Company Profile
Name
Cellectar Biosciences Inc
Sector
Industry
Phone
(608) 441-8120
Address
100 CAMPUS DRIVE, FLORHAM PARK, NJ
Compare CLRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLRB
Cellectar Biosciences Inc
|
1.53 | 65.21M | 0 | -37.75M | -30.91M | -3.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Cellectar Biosciences Inc Stock (CLRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-20 | Initiated | Oppenheimer | Outperform |
| Jan-21-20 | Resumed | ROTH Capital | Buy |
| Sep-13-19 | Initiated | ROTH Capital | Buy |
| Dec-21-16 | Initiated | Ladenburg Thalmann | Buy |
Cellectar Biosciences Inc Stock (CLRB) Latest News
Cellectar Biosciences (FRA:NV4) 3-Year Book Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Cellectar Biosciences (FRA:NV4) Margin of Safety % (DCF FCF Based) : N/A (As of Nov. 26, 2024) - GuruFocus.com
CLRB (Cellectar Biosciences) EPS without NRI : $-2.17 (TTM As of Sep. 2024) - GuruFocus.com
12,500 Shares in Cellectar Biosciences, Inc. (NASDAQ:CLRB) Purchased by Oppenheimer & Co. Inc. - Defense World
Cellectar Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.com
Roth Capital Analysts Decrease Earnings Estimates for CLRB - Defense World
Oppenheimer Lowers Cellectar Biosciences (NASDAQ:CLRB) Price Target to $12.00 - Defense World
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2024 Earnings Call Transcript - Insider Monkey
Cellectar Signs Critical Radioisotope Supply Deal for Cancer Drug Development | CLRB Stock News - StockTitan
Roth Capital Has Bearish Forecast for CLRB FY2024 Earnings - MarketBeat
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides Corporate Update - Defense World
Equities Analysts Offer Predictions for CLRB Q1 Earnings - Defense World
What is Roth Capital's Estimate for CLRB Q1 Earnings? - MarketBeat
Oppenheimer cuts Cellectar Biosciences stock target, outperform on Q3 financials - Investing.com UK
Oppenheimer Has Lowered Expectations for Cellectar Biosciences (NASDAQ:CLRB) Stock Price - MarketBeat
Cellectar Biosciences Reports Q3 2024 Financial Results - TipRanks
Cellectar Biosciences Inc (CLRB) Quarterly 10-Q Report - Quartzy
Cellectar Biosciences Inc reports results for the quarter ended September 30Earnings Summary - XM
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update - GlobeNewswire
Cellectar Biosci stock hits 52-week low at $1.82 By Investing.com - Investing.com Canada
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cellectar corrects accounting firm consent in SEC filing - Investing.com
Cellectar corrects accounting firm consent in SEC filing By Investing.com - Investing.com Australia
Earnings call: Cellectar Biosciences delays NDA submission for iopofosine I 131 - Investing.com Canada
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Short Interest Down 6.1% in October - MarketBeat
Cellectar Biosci stock hits 52-week low at $1.82 - Investing.com
Cellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Cellectar Reports Positive Phase 2 Results, Secures $19.4M in Warrant Exercises | CLRB Stock News - StockTitan
SEC Form 10-Q filed by Cellectar Biosciences Inc. - Quantisnow
Cellectar Biosciences (CLRB) Scheduled to Post Earnings on Monday - Defense World
Cellectar Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits - Quantisnow
ADAR1 Capital Management, LLC Expands Stake in Cellectar Bioscie - GuruFocus.com
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 - GlobeNewswire
Cellectar Partners With NorthStar For Ac-225 Supply - Contract Pharma
Cellectar secures Ac-225 supply for cancer drug development - Investing.com India
Cellectar Secures 10-Year Supply of Rare Cancer Treatment Isotope for Clinical Trials | CLRB Stock News - StockTitan
Cellectar Biosciences and SpectronRx Partner to Manufacture - GlobeNewswire
Cellectar Biosciences (CLRB) Scheduled to Post Quarterly Earnings on Monday - MarketBeat
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Manila Times
Cellectar Signs Key Manufacturing Deal for Breakthrough Cancer Therapy Ahead of 2025 Launch | CLRB Stock News - StockTitan
CLRB (Cellectar Biosciences) 3-Year EBITDA Growth Rate : 25.40% (As of Jun. 2024) - GuruFocus.com
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 - The Manila Times
Cellectar Biosciences to Report Third Quarter Financial - GlobeNewswire
Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 - GlobeNewswire
Cellectar's Breakthrough WM Cancer Drug Data Set for Major ASH 2024 Presentation | CLRB Stock News - StockTitan
Rosalind Advisors Inc. Increases Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - MarketBeat
S&P 500 Index (INX) QuotePress Release - The Globe and Mail
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q - GlobeNewswire
Sequoia Financial Advisors LLC Purchases New Stake in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Current and Future Analysis of Neuroblastoma Therapeutic - openPR
Waldenstrom Macroglobulinemia Market to Show Remarkable - openPR
Cellectar Biosciences Inc Stock (CLRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):